{"id":"https://openalex.org/W2017622236","doi":"https://doi.org/10.1002/ddr.20025","title":"NBI 30775 (R121919), an orally active antagonist of the corticotropin\u2010releasing factor (CRF) type\u20101 receptor for the treatment of anxiety and depression","display_name":"NBI 30775 (R121919), an orally active antagonist of the corticotropin\u2010releasing factor (CRF) type\u20101 receptor for the treatment of anxiety and depression","publication_year":2005,"publication_date":"2005-08-01","ids":{"openalex":"https://openalex.org/W2017622236","doi":"https://doi.org/10.1002/ddr.20025","mag":"2017622236"},"language":"en","primary_location":{"id":"doi:10.1002/ddr.20025","doi":"https://doi.org/10.1002/ddr.20025","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ddr.20025","pdf_url":null,"source":{"id":"https://openalex.org/S26306840","display_name":"Drug Development Research","issn_l":"0272-4391","issn":["0272-4391","1098-2299"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Development Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Chen Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Chen Chen","raw_affiliation_strings":["Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, California","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113490804","display_name":"Dimitri E. Grigoriadis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dimitri E. Grigoriadis","raw_affiliation_strings":["Department of Pharmacology, Neurocrine Biosciences, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, Neurocrine Biosciences, Inc., San Diego, California","institution_ids":["https://openalex.org/I67391869"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I67391869"],"apc_list":{"value":3980,"currency":"USD","value_usd":3980},"apc_paid":null,"fwci":0.9774,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.66435506,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"65","issue":"4","first_page":"216","last_page":"226"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10529","display_name":"Stress Responses and Cortisol","score":0.7788000106811523,"subfield":{"id":"https://openalex.org/subfields/2802","display_name":"Behavioral Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10529","display_name":"Stress Responses and Cortisol","score":0.7788000106811523,"subfield":{"id":"https://openalex.org/subfields/2802","display_name":"Behavioral Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.1436000019311905,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.052299998700618744,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crf1-receptor-antagonist","display_name":"CRF1 receptor antagonist","score":0.9290000200271606},{"id":"https://openalex.org/keywords/corticotropin-releasing-factor","display_name":"corticotropin-releasing factor","score":0.949999988079071},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.8100000023841858},{"id":"https://openalex.org/keywords/anxiety-disorders","display_name":"anxiety disorders","score":0.984000027179718},{"id":"https://openalex.org/keywords/hypothalamic-pituitary-adrenal-axis","display_name":"hypothalamic-pituitary-adrenal axis","score":0.9390000104904175},{"id":"https://openalex.org/keywords/acth-secretion","display_name":"ACTH secretion","score":0.6200000047683716},{"id":"https://openalex.org/keywords/pharmacotherapy-of-depression","display_name":"depression pharmacotherapy","score":0.5059999823570251},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.5139999985694885},{"id":"https://openalex.org/keywords/elevated-liver-enzymes","display_name":"elevated liver enzymes","score":0.6579999923706055}],"concepts":[{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.6429429650306702},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5739988088607788},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5701695680618286},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.5454207062721252},{"id":"https://openalex.org/C2778458438","wikidata":"https://www.wikidata.org/wiki/Q386664","display_name":"Corticotropin-releasing hormone","level":3,"score":0.5399271845817566},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5398302674293518},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.4745146632194519},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.4632512331008911},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4571710228919983},{"id":"https://openalex.org/C173586616","wikidata":"https://www.wikidata.org/wiki/Q5359685","display_name":"Elevated plus maze","level":3,"score":0.4392460286617279},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4075585901737213},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.1497388780117035},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/ddr.20025","doi":"https://doi.org/10.1002/ddr.20025","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ddr.20025","pdf_url":null,"source":{"id":"https://openalex.org/S26306840","display_name":"Drug Development Research","issn_l":"0272-4391","issn":["0272-4391","1098-2299"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Development Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W1527225576","https://openalex.org/W1695838946","https://openalex.org/W1822199217","https://openalex.org/W1969047053","https://openalex.org/W1977567826","https://openalex.org/W1978762354","https://openalex.org/W1981304815","https://openalex.org/W1988230174","https://openalex.org/W1991262327","https://openalex.org/W1992731869","https://openalex.org/W2009058487","https://openalex.org/W2016349238","https://openalex.org/W2020159446","https://openalex.org/W2022291557","https://openalex.org/W2038035845","https://openalex.org/W2041765925","https://openalex.org/W2044326369","https://openalex.org/W2045417336","https://openalex.org/W2045536911","https://openalex.org/W2047000216","https://openalex.org/W2053048310","https://openalex.org/W2053589842","https://openalex.org/W2055747883","https://openalex.org/W2063455379","https://openalex.org/W2071070948","https://openalex.org/W2071132017","https://openalex.org/W2075273459","https://openalex.org/W2076219468","https://openalex.org/W2081264545","https://openalex.org/W2082876506","https://openalex.org/W2095036452","https://openalex.org/W2095444610","https://openalex.org/W2107337535","https://openalex.org/W2117055641","https://openalex.org/W2122489682","https://openalex.org/W2127552596","https://openalex.org/W2143177431","https://openalex.org/W2152852639","https://openalex.org/W2153085409","https://openalex.org/W2159147558","https://openalex.org/W2175259830","https://openalex.org/W2403307686"],"related_works":["https://openalex.org/W2378180466","https://openalex.org/W2949454078","https://openalex.org/W2084407386","https://openalex.org/W1965445161","https://openalex.org/W2319758206","https://openalex.org/W2403307686","https://openalex.org/W114026363","https://openalex.org/W2034767261","https://openalex.org/W1973434549","https://openalex.org/W2484260316"],"abstract_inverted_index":{"Abstract":[0],"Since":[1],"the":[2,21,24,47,58,79,99,132,140,217,226,236,240,279],"discovery":[3],"of":[4,23,33,60,69,76,82,98,168,243,249,253],"corticotropin\u2010releasing":[5],"factor":[6,56],"(CRF),":[7],"extensive":[8],"research":[9],"has":[10,272],"attempted":[11],"to":[12,20,52,125,164,215,281],"provide":[13],"novel":[14,110,290],"treatment":[15,111],"strategies":[16],"for":[17,112,292],"diseases":[18],"related":[19],"malfunctions":[22],"hypothalamic\u2013pituitary\u2013adrenocortical":[25],"(HPA)":[26],"system.":[27],"In":[28,116,144],"depression,":[29,184],"cerebrospinal":[30],"fluid":[31],"levels":[32],"CRF":[34,44],"are":[35],"higher":[36],"than":[37],"that":[38,103],"in":[39,57,73,119,176,197,205,225,235,257,261,278],"normal":[40],"individuals.":[41],"Specifically,":[42],"increased":[43],"signaling":[45],"via":[46],"CRF1":[48,101,133,151,285],"receptor":[49,102,142,152,286],"is":[50,91],"thought":[51],"be":[53,126],"an":[54,198],"important":[55],"pathogenesis":[59],"major":[61,208],"depression":[62,223],"and":[63,95,114,183,192,294],"anxiety":[64,113,182],"disorders.":[65,296],"Consequently,":[66],"a":[67,92,108,127,250,262,275,283,289],"number":[68],"compounds":[70],"have":[71],"been":[72],"various":[74],"stages":[75],"development":[77,242],"targeting":[78],"postulated":[80],"overactivity":[81],"CRF/CRF1\u2010receptor":[83],"signaling.":[84],"NBI":[85,121,160,211],"30775,":[86],"also":[87,172],"known":[88],"as":[89,107,288],"R121919,":[90],"potent,":[93],"selective,":[94],"functional":[96,129],"antagonist":[97,130,287],"human":[100],"was":[104,123,162,213,246],"being":[105],"developed":[106],"potentially":[109],"depression.":[115],"pharmacological":[117],"assays":[118],"vitro,":[120],"30775":[122,161,212],"shown":[124],"potent":[128],"at":[131,139],"receptor,":[134],"while":[135],"having":[136],"little":[137],"affinity":[138],"CRF2":[141],"subtype.":[143],"animal":[145,178],"studies,":[146],"this":[147,244],"translated":[148],"into":[149],"central":[150],"inhibition":[153],"determined":[154],"by":[155],"ex":[156],"vivo":[157],"binding":[158],"studies.":[159],"able":[163,214],"reduce":[165,216],"stress\u2010induced":[166],"elevations":[167],"plasma":[169],"ACTH.":[170],"It":[171],"exhibited":[173],"behavioral":[174],"effects":[175,233],"several":[177],"models":[179],"measuring":[180],"both":[181],"which":[185],"included":[186],"elevate":[187],"plus":[188],"maze,":[189],"defense":[190],"withdrawal,":[191],"tail":[193],"suspension":[194],"tests.":[195],"Finally,":[196],"open\u2010label":[199],"dose\u2010escalation":[200,266],"Phase":[201,237,264],"2a":[202,238],"clinical":[203,241,270],"study":[204],"patients":[206],"with":[207],"depressive":[209],"disorder,":[210],"scores":[218],"on":[219],"self\u2010rated":[220],"or":[221],"physician\u2010administered":[222],"scales":[224],"patients.":[227],"Although":[228],"there":[229],"were":[230],"no":[231],"untoward":[232],"seen":[234],"study,":[239],"compound":[245],"discontinued":[247],"because":[248],"reversible":[251],"elevation":[252],"liver":[254],"enzyme":[255],"activity":[256],"two":[258],"healthy":[259],"volunteers":[260],"parallel":[263],"I":[265],"study.":[267],"This":[268],"first":[269],"experience":[271],"certainly":[273],"had":[274],"positive":[276],"impact":[277],"efforts":[280],"find":[282],"safe":[284],"therapeutic":[291],"depression\u2010":[293],"anxiety\u2010related":[295],"Drug":[297],"Dev.":[298],"Res.":[299],"65:216\u2013226,":[300],"2005.":[301],"\u00a9":[302],"2005":[303],"Wiley\u2010Liss,":[304],"Inc.":[305]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}